THE WIRE · № 75950
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs
01 THE MACHINE READ
WHY IT MATTERS.
A market forecast for Prader-Willi therapies cites pipeline candidates, but the report is a paid market-research promotion with no pricing or trial data.
Niche rare-disease market forecast, promotional research
Trial readouts for named candidates
Vendor-sponsored forecast, no trial data
FULL DISPATCH
The Prader-Willi syndrome market is expected to grow steadily, driven by increasing disease awareness, improved diagnosis, and the development of novel targeted therapies such as WAKIX (Harmony Biosciences), ARD-101 (Aardvark Therapeutics), PBF-999 (Palobiofarma), CSTI-500 (ConSynance...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing2026-10-12 14:42 UTC
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer2026-10-12 11:00 UTC
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting2026-10-12 11:30 UTC
Retension Pharmaceuticals exceeds target with $45M IPO2026-10-12 11:53 UTC
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway2026-10-12 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.